Collaborative Arrangements - Parion Sciences, Inc. (Details) - USD ($)		1 Months Ended
	Jun. 04, 2015	Jun. 30, 2015	Sep. 30, 2016	Dec. 31, 2015
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net [Abstract]
Intangible assets			$ 284,340,000	$ 284,340,000
Deferred tax liability, net			(133,270,000)	(110,439,000)
Goodwill			$ 50,384,000	$ 50,384,000
Parion Sciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Business Acquisition Contingent Consideration Commercial Milestones And Royalties Discount Rate	6.60%
Prior to marketing approval, time period of notice required to terminate (in days)		90 days
Subsequent to marketing approval, time period of notice required to terminate (in days)		180 days
Change of control prior to clinical trial, time period of notice required to terminate (in days)		30 days
Term of agreement following first commercial sale (in years)		10 years
Business Acquisition Contingent Consideration Development Milestones Discount Rate Low End Of Range	4.10%
Business Acquisition Contingent Consideration Development Milestones Discount Rate High End Of Range	5.90%
Business Combination, Consideration Transferred [Abstract]
Up-front payment	$ 80,000,000	$ 80,000,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	175,340,000
Business Combination, Consideration Transferred	255,340,000
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net [Abstract]
Intangible assets	255,340,000	255,300,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	(164,317,000)
Deferred tax liability, net	(91,023,000)
Other Liabilities Assets Net	(10,468,000)
Goodwill	$ 10,468,000
ENaC Inhibitors in CF | Parion Sciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum		490,000,000
Collaborative arrangement regulatory potential milestone payments maximum, global filling and approval		360,000,000
Enac Inhibitors in Non Cf | Parion Sciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum		370,000,000
Additional Enac Inhibitors | Parion Sciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum		$ 230,000,000